1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Abbott Laboratories

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
Robert Ford

100 Abbott Park Rd
Abbott Park, Illinois 60064-3500
Phone: 12246676100


At 6.3% CAGR of U.S. Clinical Nutrition Market Expected to Expand at a Steady 2024-2031 | Abbott Laboratories, Sanofi
May 17, 2024 12:54pm

BURLINGAME, CALIFORNIA, UNITED STATES, May 17, 2024 /⁨EINPresswire.com⁩/ -- Coherent Market Insights has recently published comprehensive business research on “U.S. Clinical Nutrition Market” which includes historic data, present market trends, …

Source:EIN News Healthcare
The GT3 drivers we want to see at Le Mans next
May 10, 2024 11:15am

Source:Kwhen Finance
Amazon, Abbott Laboratories And 2 Other Stocks Insiders Are Selling
May 09, 2024 12:35pm

The Nasdaq 100 closed slightly lower on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company''s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Zoom Video Communications The Trade: Zoom Video Communications, Inc. (NASDAQ: ZM ) CEO Eric S. Yuan sold a total of 4,840 shares at an average price of $61.97. The insider received around $299,911 from selling those shares. What''s Happening: Zoom Video … Full story available on Benzinga.com

What the Options Market Tells Us About Abbott Laboratories
May 01, 2024 20:46pm

Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories (NYSE: ABT ), and it''s something market players shouldn''t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABT usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga''s options scanner highlighted 8 extraordinary options activities for Abbott Laboratories. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 5 are puts, totaling $240,592, and 3 are calls, amounting to $244,878. Expected Price Movements Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $105.0 to $130.0 for Abbott Laboratories over the recent three months.

Abbott Labs EVP of Finance Robert Funck Retires After 36 Years
May 01, 2024 20:13pm

Abbott Labs (ABT) has shared an update. After a notable 36-year tenure with Abbott Laboratories, Robert E. Funck, Jr., the Executive Vice President…

Stock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices Plunge
May 01, 2024 19:57pm

Healthcare stocks certainly haven’t set the world on fire lately. The S&P Health Care Index is up 3% so far in 2024 compared to an 8% gain in the benchmark S&P 500 . Yet, many leading healthcare companies just issued better-than-expected financial results for this year’s first quarter. Additionally, these stocks tend to perform well during presidential election years. Why? Healthcare is often an issue for candidates on the campaign trail. Many analysts expect healthcare stocks to outperform going forward, especially since health securities can act as a defensive play during times of market volatility. That unpredictability could worsen in coming months should the timing of interest rates get pushed out further. Or, we could run into problems caused by stagflation , i.e. when inflation continues to rise as the economy slows. So, let’s examine three worthy healthcare stocks to buy and hold should prices plunge. Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com Abbott Laboratories (NYSE: ABT ) just reported strong first-quarter financial results due to robust sales of its medical devices, notably its glucose-monitoring product.

Abbott''s Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod
Apr 29, 2024 14:30pm

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) Monday announced that the U.S. Food and Drug Administration has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System for patien…

Source:Finanz Nachrichten
Barclays cuts Abbott Labs stock target, maintains Overweight
Apr 22, 2024 16:34pm


3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
Apr 22, 2024 12:00pm

Dividend stocks have a proven record of stock market outperformance. For nearly 100 years, income-generating stocks on the S&P 500 have beaten non-payers. There has never been a decade when dividend stocks didn’t produce a positive return. And then we have the dividend royalty, companies that have raised their payouts the longest. These Dividend Kings have increased their dividends every year for 50 years or more without fail. Through wars, recessions and global pandemics, these businesses kept rewarding their investors for sticking by them. That doesn’t mean, however, their stocks will always go up. Economic factors and global events can temporarily slow business, causing investors to seek out faster growing stocks. But over time the Dividend Kings always rebound, explaining why they can still claim their thrones. The following are three royal dividend payers whose stocks are down 10% or more this year. You might want to consider buying these dividend stocks before they rebound once more.

Why I Believe Abbott Is Much Better Positioned In Today''s Rising Inflation Scenario
Apr 22, 2024 05:16am

Abbott Laboratories'' core business remains robust, with impressive performance across its segments. See why ABT stock is a Buy.

Source:Seeking Alpha